Tvardi Therapeutics Free Cash Flow (FCF) History (TVRD)
Tvardi Therapeutics reported −$19.4M in free cash flow for fiscal 2024, an increase of $75.1M from the previous fiscal year, with a free cash flow margin of −271.14%.
View full Tvardi Therapeutics company overviewTvardi Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$19.4M | $75.1M | — | −271.14% |
| 2023 | 2023-12-31 | −$94.5M | −$15.7M | — | −450.46% |
| 2022 | 2022-12-31 | −$78.8M | −$18.6M | — | −188.15% |
| 2021 | 2021-12-31 | −$60.1M | −$54.3M | — | −261.10% |
| 2020 | 2020-12-31 | −$5.8M | $103.4M | — | −4.32% |
| 2019 | 2019-12-31 | −$109.2M | −$86.9M | — | −549.35% |
| 2018 | 2018-12-31 | −$22.4M | $32.5M | — | −166.11% |
| 2017 | 2017-12-31 | −$54.9M | −$6.8M | — | −6024.70% |
| 2016 | 2016-12-31 | −$48.1M | −$26.6M | — | −55927.91% |
| 2015 | 2015-12-31 | −$21.5M | −$3.8M | — | −565.29% |
| 2014 | 2014-12-31 | −$17.7M | −$20.5M | — | −556.63% |
| 2013 | 2013-12-31 | $2.8M | — | — | +23.60% |
Tvardi Therapeutics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$4.8M | $18.7M | — | −332.16% |
| Q3 2024 | 2024-09-30 | −$6.7M | $18.5M | — | −260.37% |
| Q2 2024 | 2024-06-30 | $23.4M | $27.9M | — | +2363.87% |
| Q1 2024 | 2024-03-31 | −$31.3M | −$5.7M | — | −1465.53% |
| Q4 2022 | 2022-12-31 | −$23.5M | $7.7M | — | −720.94% |
| Q3 2022 | 2022-09-30 | −$25.2M | $445,000 | — | −232.98% |
| Q2 2022 | 2022-06-30 | −$4.5M | $20.4M | — | −19.58% |
| Q1 2022 | 2022-03-31 | −$25.6M | $2.0M | — | −533.78% |
| Q4 2019 | 2019-12-31 | −$31.2M | −$6.8M | — | −690.89% |
| Q3 2019 | 2019-09-30 | −$25.6M | −$5.1M | — | −443.16% |
| Q2 2019 | 2019-06-30 | −$24.9M | −$65.9M | — | −478.17% |
| Q1 2019 | 2019-03-31 | −$27.5M | −$9.1M | — | −628.41% |
| Q4 2018 | 2018-12-31 | −$24.4M | −$13.0M | — | — |
| Q3 2018 | 2018-09-30 | −$20.5M | −$10.6M | — | −405.37% |
| Q2 2018 | 2018-06-30 | $41.0M | $53.0M | — | +1426.62% |
| Q1 2018 | 2018-03-31 | −$18.5M | $3.2M | — | — |
| Q4 2017 | 2017-12-31 | −$11.4M | $1.8M | — | — |
| Q3 2017 | 2017-09-30 | −$9.9M | $3.5M | — | — |
| Q2 2017 | 2017-06-30 | −$11.9M | −$340,000 | — | — |
| Q1 2017 | 2017-03-31 | −$21.6M | −$11.8M | — | −2375.85% |
| Q4 2016 | 2016-12-31 | −$13.3M | −$9.1M | — | — |
| Q3 2016 | 2016-09-30 | −$13.4M | −$5.6M | — | −16950.63% |
| Q2 2016 | 2016-06-30 | −$11.6M | −$7.3M | — | −14694.94% |
| Q1 2016 | 2016-03-31 | −$9.8M | −$4.6M | — | −140585.71% |
| Q4 2015 | 2015-12-31 | −$4.2M | $334,000 | — | — |
| Q3 2015 | 2015-09-30 | −$7.8M | — | — | −320.33% |
| Q2 2015 | 2015-06-30 | −$4.3M | — | — | −487.41% |
| Q1 2015 | 2015-03-31 | −$5.2M | — | — | −1073.01% |
| Q3 2014 | 2014-09-30 | −$4.5M | — | — | −400.80% |
Tvardi Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$109.2M to −$19.4M, a net increase of $89.9M. Tvardi Therapeutics's latest reported quarter, Q4 2024, generated −$4.8M in free cash flow, an increase of $18.7M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tvardi Therapeutics filings at SEC.gov ↗